<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460338</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101172</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic posed significant challenges worldwide, with SARS-CoV-2 vaccines critical in reducing morbidity and mortality. This study evaluates the immunogenicity and antibody persistence of the BNT162b2 vaccine in people living with HIV (PLWH).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We monitored anti-SARS-CoV-2 Spike IgG concentration in a cohort of PLWH at five time points (T0-T4) using chemiluminescent microparticle immunoassays (CMIAs) at the baselined both during and after vaccination. In severely immunocompromised individuals, a boosting dose was recommended, and participants and IgG concentration were measured in the two subgroups (boosted and not boosted).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 165 PLWH were included, and 83% were male with a median age of 55 years (IQR: 47-62). At T1, 161 participants (97.6%) showed seroconversion with a median of IgG values of 468.8 AU/mL (IQR: 200.4-774.3 AU/mL). By T2, all subjects maintained a positive result, with the median anti-SARS-CoV-2 Spike IgG concentration increasing to 6191.6 AU/mL (IQR: 3666.7-10,800.8 AU/mL). At T3, all participants kept their antibody levels above the positivity threshold with a median of 1694.3 AU/mL (IQR: 926.3-2966.4 AU/mL). At T4, those without a booster dose exhibited a marked decrease to a median of 649.1 AU/mL (IQR: 425.5-1299.8 AU/mL), whereas those with a booster experienced a significant increase to a median of 13,105.2 AU/mL (IQR: 9187.5-18,552.1 AU/mL). The immune response was negatively influenced by the presence of dyslipidaemia at T1 (aOR 4.75, 95% CI: 1.39-16.20) and diabetes at T3 (aOR 7.11, 95% CI: 1.10-46.1), while the use of protease inhibitors (aORs 0.06, 95% CI: 0.01-0.91) and being female (aOR 0.02, 95% CI: 0.01-0.32) at T3 were protective factors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The immunogenicity of the BNT162b2 vaccine in PLWH has been confirmed, with booster doses necessary to maintain high levels of anti-SARS-CoV-2 Spike IgG antibodies, especially in patients with comorbidities. These findings underline the importance of a personalized vaccination strategy in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldovin</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7375-9187</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geppini</LastName><ForeName>Ruggero</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5655-8105</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miatton</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-7909-7294</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amoruso</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4954-5848</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonzo</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoncello</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4040-8601</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finco</LastName><ForeName>Mascia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzitelli</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0263-0703</Identifier><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasset</LastName><ForeName>Lolita</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattelan</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2869-2945</Identifier><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35131 Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldo</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-6012-9453</Identifier><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">PLWH</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody persistence</Keyword><Keyword MajorTopicYN="N">booster dose</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest in the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460338</ArticleId><ArticleId IdType="pmc">PMC11512344</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101172</ArticleId><ArticleId IdType="pii">vaccines12101172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323:1824–1836. doi: 10.1001/jama.2020.6019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Coronavirus (COVID-19) Dashboard with Vaccination Data.  [(accessed on 5 October 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Patel R., Kaki M., Potluri V.S., Kahar P., Khanna D. A Comprehensive Review of SARS-CoV-2 Vaccines: Pfizer, Moderna &amp; Johnson &amp; Johnson. Hum. Vaccin. Immunother. 2022;18:2002083. doi: 10.1080/21645515.2021.2002083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2002083</ArticleId><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y.Y., Li J.X., Hu Y.M., Hu Y.S., Zeng G., Zhu F.C. Quadrivalent Influenza Vaccine (Sinovac Biotech) for Seasonal Influenza Prophylaxis. Expert. Rev. Vaccines. 2021;20:1–11. doi: 10.1080/14760584.2021.1875823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1875823</ArticleId><ArticleId IdType="pubmed">33434084</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater J., Ewer K.J., Ogbe A., Pace M., Adele S., Adland E., Alagaratnam J., Aley P.K., Ali M., Ansari M.A., et al. Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a Phase 2/3 Clinical Trial. Lancet HIV. 2021;8:e474–e485. doi: 10.1016/S2352-3018(21)00103-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00103-X</ArticleId><ArticleId IdType="pmc">PMC8213361</ArticleId><ArticleId IdType="pubmed">34153264</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi S.A., Koen A.L., Izu A., Fairlie L., Cutland C.L., Baillie V., Padayachee S.D., Dheda K., Barnabas S.L., Bhorat Q.E., et al. Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without HIV in South Africa: An Interim Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 1B/2A Trial. Lancet HIV. 2021;8:e568–e580. doi: 10.1016/S2352-3018(21)00157-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00157-0</ArticleId><ArticleId IdType="pmc">PMC8372504</ArticleId><ArticleId IdType="pubmed">34416193</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel B.A., Karaba A.H., Garliss C.C., Beck E.J., Wang K.H., Laeyendecker O., Cox A.L., Blankson J.N. The BNT162b2 MRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) Clin. Infect. Dis. 2022;74:1268–1270. doi: 10.1093/cid/ciab648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab648</ArticleId><ArticleId IdType="pmc">PMC8406881</ArticleId><ArticleId IdType="pubmed">34293114</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakharia N., Subramanian A.K., Shapiro A.E. COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. Infect. Dis. Clin. N. Am. 2022;36:397–421. doi: 10.1016/j.idc.2022.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2022.01.006</ArticleId><ArticleId IdType="pmc">PMC8806148</ArticleId><ArticleId IdType="pubmed">35636907</ArticleId></ArticleIdList></Reference><Reference><Citation>Napuri N.I., Curcio D., Swerdlow D.L., Srivastava A. Immune Response to COVID-19 and MRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infect. Dis. Ther. 2022;11:1391–1414. doi: 10.1007/s40121-022-00648-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00648-2</ArticleId><ArticleId IdType="pmc">PMC9132351</ArticleId><ArticleId IdType="pubmed">35614299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin Lee A.R.Y., Wong S.Y., Chai L.Y.A., Lee S.C., Lee M.X., Muthiah M.D., Tay S.H., Teo C.B., Tan B.K.J., Chan Y.H., et al. Efficacy of Covid-19 Vaccines in Immunocompromised Patients: Systematic Review and Meta-Analysis. BMJ. 2022;376:e068632. doi: 10.1136/BMJ-2021-068632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra A.R., Kobayashi T., Suzuki H., Alsuhaibani M., Hasegawa S., Tholany J., Perencevich E., Maezato A.M., Ricardo V.C.V., Salinas J.L., et al. The Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccine in the Prevention of Post–COVID-19 Conditions: A Systematic Literature Review and Meta-Analysis. Antimicrob. Steward. Healthc. Epidemiol. 2022;2:e192. doi: 10.1017/ash.2022.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.336</ArticleId><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q., Bates B., Shao Y.R., Hsu F.C., Liu F., Madhira V., Mitra A.K., Bergquist T., Kavuluru R., Li X., et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative. J. Clin. Oncol. 2022;40:1414–1427. doi: 10.1200/JCO.21.02419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02419</ArticleId><ArticleId IdType="pmc">PMC9061155</ArticleId><ArticleId IdType="pubmed">35286152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M., Trunfio M., Sasset L., Leoni D., Castelli E., Lo Menzo S., Gardin S., Putaggio C., Brundu M., Garzotto P., et al. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. Viruses. 2022;14:493. doi: 10.3390/v14030493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030493</ArticleId><ArticleId IdType="pmc">PMC8954437</ArticleId><ArticleId IdType="pubmed">35336900</ArticleId></ArticleIdList></Reference><Reference><Citation>Augello M., Bono V., Rovito R., Tincati C., Marchetti G. Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? Curr. HIV/AIDS Rep. 1904;1:3. doi: 10.1007/s11904-023-00647-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-023-00647-z</ArticleId><ArticleId IdType="pmc">PMC9860243</ArticleId><ArticleId IdType="pubmed">36680700</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO) Clinical Features and Prognostic Factors of COVID-19 in People Living with HIV Hospitalized with Suspected or Confirmed SARS-CoV-2 Infection. WHO; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Ssentongo P., Heilbrunn E.S., Ssentongo A.E., Advani S., Chinchilli V.M., Nunez J.J., Du P. Epidemiology and Outcomes of COVID-19 in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Sci. Rep. 2021;11:6283. doi: 10.1038/s41598-021-85359-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85359-3</ArticleId><ArticleId IdType="pmc">PMC7973415</ArticleId><ArticleId IdType="pubmed">33737527</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffito M., Waters L. More Evidence for Worse COVID-19 Outcomes in People with HIV. Lancet HIV. 2021;8:e661. doi: 10.1016/S2352-3018(21)00272-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00272-1</ArticleId><ArticleId IdType="pmc">PMC8514199</ArticleId><ArticleId IdType="pubmed">34655548</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors Associated with COVID-19-Related Death Using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Danwang C., Noubiap J.J., Robert A., Yombi J.C. Outcomes of Patients with HIV and COVID-19 Co-Infection: A Systematic Review and Meta-Analysis. AIDS Res. Ther. 2022;19:3. doi: 10.1186/s12981-021-00427-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12981-021-00427-y</ArticleId><ArticleId IdType="pmc">PMC8759058</ArticleId><ArticleId IdType="pubmed">35031068</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff B.J., Ramírez-Suástegui C., Fajardo V., Chee S.J., Kusnadi A., Simon H., Eschweiler S., Grifoni A., Pelosi E., Weiskopf D., et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell. 2020;183:1340–1353. doi: 10.1016/j.cell.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosioni J., Blanco J.L., Reyes-Urueña J.M., Davies M.A., Sued O., Marcos M.A., Martínez E., Bertagnolio S., Alcamí J., Miro J.M., et al. Overview of SARS-CoV-2 Infection in Adults Living with HIV. Lancet HIV. 2021;8:e294–e305. doi: 10.1016/S2352-3018(21)00070-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00070-9</ArticleId><ArticleId IdType="pmc">PMC8075775</ArticleId><ArticleId IdType="pubmed">33915101</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomah D.K., Reyes-Urueña J., Díaz Y., Moreno S., Aceiton J., Bruguera A., Vivanco-Hidalgo R.M., Llibre J.M., Domingo P., Falcó V., et al. Sociodemographic, Clinical, and Immunological Factors Associated with SARS-CoV-2 Diagnosis and Severe COVID-19 Outcomes in People Living with HIV: A Retrospective Cohort Study. Lancet HIV. 2021;8:e701–e710. doi: 10.1016/S2352-3018(21)00240-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00240-X</ArticleId><ArticleId IdType="pmc">PMC8514194</ArticleId><ArticleId IdType="pubmed">34655549</ArticleId></ArticleIdList></Reference><Reference><Citation>Augello M., Bono V., Rovito R., Tincati C., D’Arminio Monforte A., Marchetti G. Six-Month Immune Responses to MRNA-1273 Vaccine in Combination Antiretroviral Therapy Treated Late Presenter People with HIV According to Previous SARS-CoV-2 Infection. AIDS. 2023;37:1503–1517. doi: 10.1097/QAD.0000000000003585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003585</ArticleId><ArticleId IdType="pmc">PMC10355808</ArticleId><ArticleId IdType="pubmed">37199415</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoham S., Batista C., Ben Amor Y., Ergonul O., Hassanain M., Hotez P., Kang G., Kim J.H., Lall B., Larson H.J., et al. Vaccines and Therapeutics for Immunocompromised Patients with COVID-19. eClinicalMedicine. 2023;59:101965. doi: 10.1016/j.eclinm.2023.101965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101965</ArticleId><ArticleId IdType="pmc">PMC10091856</ArticleId><ArticleId IdType="pubmed">37070102</ArticleId></ArticleIdList></Reference><Reference><Citation>El Chaer F., El Sahly H.M. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am. J. Med. 2019;132:437–446. doi: 10.1016/j.amjmed.2018.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.12.011</ArticleId><ArticleId IdType="pubmed">30611828</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I., Wieder-Finesod A., Litchevsky V., Biber A., Indenbaum V., Olmer L., Huppert A., Mor O., Goldstein M., Levin E.G., et al. Immunogenicity and Safety of the BNT162b2 MRNA COVID-19 Vaccine in People Living with HIV-1. Clin. Microbiol. Infect. 2021;27:1851–1855. doi: 10.1016/j.cmi.2021.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.07.031</ArticleId><ArticleId IdType="pmc">PMC8382485</ArticleId><ArticleId IdType="pubmed">34438069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernéis S., Launay O., Turbelin C., Batteux F., Hanslik T., Boëlle P.Y. Long-Term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2014;58:1130–1139. doi: 10.1093/cid/cit937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit937</ArticleId><ArticleId IdType="pmc">PMC4761378</ArticleId><ArticleId IdType="pubmed">24415637</ArticleId></ArticleIdList></Reference><Reference><Citation>Geretti A.M., Brook G., Cameron C., Chadwick D., French N., Heyderman R., Ho A., Hunter M., Ladhani S., Lawton M., et al. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med. 2016;17((Suppl. S3)):s2–s81. doi: 10.1111/hiv.12424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.12424</ArticleId><ArticleId IdType="pubmed">27568789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena G., García-Basteiro A.L., Bayas J.M. Hepatitis B and A Vaccination in HIV-Infected Adults: A Review. Hum. Vaccin. Immunother. 2015;11:2582–2598. doi: 10.1080/21645515.2015.1055424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1055424</ArticleId><ArticleId IdType="pmc">PMC4685678</ArticleId><ArticleId IdType="pubmed">26208678</ArticleId></ArticleIdList></Reference><Reference><Citation>George V.K., Pallikkuth S., Parmigiani A., Alcaide M., Fischl M., Arheart K.L., Pahwa S. HIV Infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine. J. Infect. Dis. 2015;211:1959–1968. doi: 10.1093/infdis/jiu840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu840</ArticleId><ArticleId IdType="pmc">PMC4836723</ArticleId><ArticleId IdType="pubmed">25556252</ArticleId></ArticleIdList></Reference><Reference><Citation>Noe S., Ochana N., Wiese C., Schabaz F., Von Krosigk A., Heldwein S., Rasshofer R., Wolf E., Jonsson-Oldenbuettel C. Humoral Response to SARS-CoV-2 Vaccines in People Living with HIV. Infection. 2022;50:617–623. doi: 10.1007/s15010-021-01721-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01721-7</ArticleId><ArticleId IdType="pmc">PMC8543429</ArticleId><ArticleId IdType="pubmed">34694595</ArticleId></ArticleIdList></Reference><Reference><Citation>Brumme Z.L., Mwimanzi F., Lapointe H.R., Cheung P.K., Sang Y., Duncan M.C., Yaseen F., Agafitei O., Ennis S., Ng K., et al. Humoral Immune Responses to COVID-19 Vaccination in People Living with HIV Receiving Suppressive Antiretroviral Therapy. NPJ Vaccines. 2022;7:28. doi: 10.1038/s41541-022-00452-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00452-6</ArticleId><ArticleId IdType="pmc">PMC8885829</ArticleId><ArticleId IdType="pubmed">35228535</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergori A., Cozzi-Lepri A., Matusali G., Cicalini S., Bordoni V., Meschi S., Mazzotta V., Colavita F., Fusto M., Cimini E., et al. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after MRNA Vaccine in Persons Living with HIV. Vaccines. 2023;11:1739. doi: 10.3390/vaccines11121739.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121739</ArticleId><ArticleId IdType="pmc">PMC10747871</ArticleId><ArticleId IdType="pubmed">38140145</ArticleId></ArticleIdList></Reference><Reference><Citation>Touizer E., Alrubayyi A., Ford R., Hussain N., Gerber P.P., Shum H.L., Rees-Spear C., Muir L., Gea-Mallorquí E., Kopycinski J., et al. Attenuated Humoral Responses in HIV after SARS-CoV-2 Vaccination Linked to B Cell Defects and Altered Immune Profiles. iScience. 2023;26:105862. doi: 10.1016/j.isci.2022.105862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105862</ArticleId><ArticleId IdType="pmc">PMC9788849</ArticleId><ArticleId IdType="pubmed">36590902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang L., Shang W., Gao P., Wang Y., Liu J., Liu M. Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis. Vaccines. 2022;10:1569. doi: 10.3390/vaccines10091569.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091569</ArticleId><ArticleId IdType="pmc">PMC9503586</ArticleId><ArticleId IdType="pubmed">36146647</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano E., Ricciardi A., Casciaro R., Pallara E., De Vita E., Bavaro D.F., Larocca A.M.V., Stefanizzi P., Tafuri S., Saracino A. Immunogenicity and Safety of the BNT162b2 COVID-19 MRNA Vaccine in PLWH: A Monocentric Study in Bari, Italy. J. Med. Virol. 2022;94:2230–2236. doi: 10.1002/jmv.27629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27629</ArticleId><ArticleId IdType="pmc">PMC9015486</ArticleId><ArticleId IdType="pubmed">35106771</ArticleId></ArticleIdList></Reference><Reference><Citation>EACS—European AIDS Clinical Society . EACS Guidelines—Version 10.0 November 20. EACS; Brussels, Belgium: 2020.</Citation></Reference><Reference><Citation>Pfizer Manufacturing Belgium  NV PFIZER-BIONTECH COVID-19 VACCINE—Bnt162b2 Injection, Suspension.  [(accessed on 13 December 2023)].  Available online:  https://labeling.pfizer.com/ShowLabeling.aspx?id=14471.</Citation></Reference><Reference><Citation>Ministero della Salute  Direzione Generale Della Prevenzione Sanitaria Circolare, Ministero Della Salute n. 43604 Del 27-09-2021.  [(accessed on 10 October 2024)];2021  Available online:  https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&amp;codLeg=82953&amp;parte=1%20&amp;serie=null.</Citation></Reference><Reference><Citation>Parodi E., Jones G., Maclean W. Italy Approves Booster COVID-19 Shots for Vulnerable Groups|Reuters.  [(accessed on 13 December 2023)].  Available online:  https://www.reuters.com/world/europe/italy-approves-booster-covid-19-shots-vulnerable-groups-2021-09-09/</Citation></Reference><Reference><Citation>Ebinger J.E., Fert-Bober J., Printsev I., Wu M., Sun N., Prostko J.C., Frias E.C., Stewart J.L., Van Eyk J.E., Braun J.G., et al. Antibody Responses to the BNT162b2 MRNA Vaccine in Individuals Previously Infected with SARS-CoV-2. Nat. Med. 2021;27:981–984. doi: 10.1038/s41591-021-01325-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01325-6</ArticleId><ArticleId IdType="pmc">PMC8205849</ArticleId><ArticleId IdType="pubmed">33795870</ArticleId></ArticleIdList></Reference><Reference><Citation>Speich B., Chammartin F., Abela I.A., Amico P., Stoeckle M.P., Eichenberger A.L., Hasse B., Braun D.L., Schuurmans M.M., Müller T.F., et al. Antibody Response in Immunocompromised Patients after the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or MRNA-1273: A Randomized Controlled Trial. Clin. Infect. Dis. 2022;75:E585–E593. doi: 10.1093/cid/ciac169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac169</ArticleId><ArticleId IdType="pmc">PMC8903480</ArticleId><ArticleId IdType="pubmed">35234868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Chen Y., Li Y., Wang C., Zhang X. Immunogenicity and Efficacy of COVID-19 Vaccines in People Living with HIV: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 2022;124:212–223. doi: 10.1016/j.ijid.2022.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.10.005</ArticleId><ArticleId IdType="pmc">PMC9553964</ArticleId><ArticleId IdType="pubmed">36241168</ArticleId></ArticleIdList></Reference><Reference><Citation>Portillo V., Fedeli C., Ustero Alonso P., Petignat I., Mereles Costa E.C., Sulstarova A., Jaksic C., Yerly S., Calmy A. Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals. Front. Immunol. 2022;12:820126. doi: 10.3389/fimmu.2021.820126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.820126</ArticleId><ArticleId IdType="pmc">PMC8866244</ArticleId><ArticleId IdType="pubmed">35222357</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergori A., Cozzi Lepri A., Cicalini S., Matusali G., Bordoni V., Lanini S., Meschi S., Iannazzo R., Mazzotta V., Colavita F., et al. Immunogenicity to COVID-19 MRNA Vaccine Third Dose in People Living with HIV. Nat. Commun. 2022;13:4922. doi: 10.1038/s41467-022-32263-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32263-7</ArticleId><ArticleId IdType="pmc">PMC9395398</ArticleId><ArticleId IdType="pubmed">35995780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianserra L., Donà M.G., Giuliani E., Stingone C., Pontone M., Buonomini A.R., Giuliani M., Pimpinelli F., Morrone A., Latini A. Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective CART. Vaccines. 2022;10:1243. doi: 10.3390/vaccines10081243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081243</ArticleId><ArticleId IdType="pmc">PMC9414483</ArticleId><ArticleId IdType="pubmed">36016131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowokan A., Samji H., Puyat J.H., Janjua N.Z., Wilton J., Wong J., Grennan T., Chambers C., Kroch A., Costiniuk C.T., et al. Effectiveness of COVID-19 Vaccines in People Living with HIV in British Columbia and Comparisons with a Matched HIV-Negative Cohort: A Test-Negative Design. Int. J. Infect. Dis. 2023;127:162–170. doi: 10.1016/j.ijid.2022.11.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.11.035</ArticleId><ArticleId IdType="pmc">PMC9711901</ArticleId><ArticleId IdType="pubmed">36462571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamacchia G., Salvati L., Kiros S.T., Mazzoni A., Vanni A., Capone M., Carnasciali A., Farahvachi P., Lagi F., Di Lauria N., et al. Fourth Dose of MRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH) Biomedicines. 2022;10:3261. doi: 10.3390/biomedicines10123261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10123261</ArticleId><ArticleId IdType="pmc">PMC9775459</ArticleId><ArticleId IdType="pubmed">36552017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Alós L., Armenteros J.J.A., Madsen J.R., Hansen C.B., Jarlhelt I., Hamm S.R., Heftdal L.D., Pries-Heje M.M., Møller D.L., Fogh K., et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat. Commun. 2022;13:1614. doi: 10.1038/s41467-022-29225-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29225-4</ArticleId><ArticleId IdType="pmc">PMC8960902</ArticleId><ArticleId IdType="pubmed">35347129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuan J.J., Zapata H., Critch-Gilfillan T., Ryall L., Turcotte B., Mutic S., Andrews L., Roh M.E., Friedland G., Barakat L., et al. Qualitative Assessment of Anti-SARS-CoV-2 Spike Protein Immunogenicity (QUASI) after COVID-19 Vaccination in Older People Living with HIV. HIV Med. 2022;23:178–185. doi: 10.1111/hiv.13188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.13188</ArticleId><ArticleId IdType="pmc">PMC8652674</ArticleId><ArticleId IdType="pubmed">34632695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Chung H., Lee J.E., Kim J., Hwang J., Chung Y. Immunologic Aspects of Dyslipidemia: A Critical Regulator of Adaptive Immunity and Immune Disorders. J. Lipid Atheroscler. 2021;10:184. doi: 10.12997/jla.2021.10.2.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.12997/jla.2021.10.2.184</ArticleId><ArticleId IdType="pmc">PMC8159760</ArticleId><ArticleId IdType="pubmed">34095011</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh G.C.K.W., Peacock S.J., Van Der Poll T., Wiersinga W.J. The Impact of Diabetes on the Pathogenesis of Sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 2011;31:379–388. doi: 10.1007/s10096-011-1337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-011-1337-4</ArticleId><ArticleId IdType="pmc">PMC3303037</ArticleId><ArticleId IdType="pubmed">21805196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran L., Tam D.N.H., Elhadad H., Hien N.M., Huy N.T. Evaluation of COVID-19 Protease and HIV Inhibitors Interactions. Acta Pharm. 2021;72:1–8. doi: 10.2478/acph-2022-0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/acph-2022-0010</ArticleId><ArticleId IdType="pubmed">36651526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Li Q., Xie Y., Jianyuan Z., Yi D., Guo S., Guo F., Wang J., Yang L., Cen S. Repurposing of HIV/HCV Protease Inhibitors against SARS-CoV-2 3CLpro. Antivir. Res. 2022;207:105419. doi: 10.1016/j.antiviral.2022.105419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105419</ArticleId><ArticleId IdType="pmc">PMC9499987</ArticleId><ArticleId IdType="pubmed">36155070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouznetsova V.L., Huang D.Z., Tsigelny I.F. Potential SARS-CoV-2 Protease Mpro Inhibitors: Repurposing FDA-Approved Drugs. Phys. Biol. 2021;18:025001. doi: 10.1088/1478-3975/abcb66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1478-3975/abcb66</ArticleId><ArticleId IdType="pubmed">33203811</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi M., Mótyán J.A., Szojka Z.I., Golda M., Miczi M., Tőzsér J. Analysis of the Efficacy of HIV Protease Inhibitors against SARS-CoV-2’s Main Protease. Virol. J. 2020;17:190. doi: 10.1186/s12985-020-01457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01457-0</ArticleId><ArticleId IdType="pmc">PMC7689640</ArticleId><ArticleId IdType="pubmed">33243253</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer S., Bojkova D., Cinatl J., Van Damme E., Buyck C., Van Loock M., Woodfall B., Ciesek S. Lack of Antiviral Activity of Darunavir against SARS-CoV-2. Int. J. Infect. Dis. 2020;97:7–10. doi: 10.1016/j.ijid.2020.05.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.085</ArticleId><ArticleId IdType="pmc">PMC7258847</ArticleId><ArticleId IdType="pubmed">32479865</ArticleId></ArticleIdList></Reference><Reference><Citation>Baazim H., Antonio-Herrera L., Bergthaler A. The Interplay of Immunology and Cachexia in Infection and Cancer. Nat. Rev. Immunol. 2022;22:309–321. doi: 10.1038/s41577-021-00624-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00624-w</ArticleId><ArticleId IdType="pmc">PMC8489366</ArticleId><ArticleId IdType="pubmed">34608281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortellini E., Zingaropoli M.A., Mancarella G., Marocco R., Carraro A., Jamhour M., Barbato C., Guardiani M., Dominelli F., Pasculli P., et al. Quality of T-Cell Response to SARS-CoV-2 MRNA Vaccine in ART-Treated PLWH. Int. J. Mol. Sci. 2022;23:14988. doi: 10.3390/ijms232314988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232314988</ArticleId><ArticleId IdType="pmc">PMC9741180</ArticleId><ArticleId IdType="pubmed">36499317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>